

## Estimates compiled by Modular Finance on behalf of XVIVO Perfusion.

Number of contributors: 6 (all of which have been updated or confirmed before the report)

| KPI                                  | Q1 2024E |
|--------------------------------------|----------|
| Net sales (MSEK)                     | 165      |
| Organic growth in local currency (%) | 15.8     |
| Gross profit (MSEK)                  | 123      |
| EBIT (MSEK)                          | 9        |
| EBITDA (MSEK)                        | 26       |
| Net profit (MSEK)                    | 8        |
| Earnings per share (SEK)             | 0.25     |
| Net sales per segment:               |          |
| Thoracic (MSEK)                      | 103      |
| Abdominal (MSEK)                     | 40       |
| Services (MSEK)                      | 22       |

XVIVO Perfusion's Q1 report will be released on Wednesday, 24 April, at 07:30 am CEST.